Sorafenib: Experience and Better Manage­ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis

BACKGROUND: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. METHODS: This was a retrospective study of advanced HCC patients treat...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Liver Cancer
मुख्य लेखकों: Raoul, Jean-Luc, Adhoute, Xavier, Penaranda, Guillaume, Perrier, Hervé, Castellani, Paul, Oules, Valérie, Bourlière, Marc
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: S. Karger AG 2019
विषय:
Original Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883434/
https://ncbi.nlm.nih.gov/pubmed/31799203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497161
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन